New agents modulating the renin-angiotensin-aldosterone system--Will there be a new therapeutic option?

This article briefly describes new molecules affecting the RAAS, namely: recombinant human ACE2, ACE2 activators, angiotensin-(1-7) peptide and non-peptide analogs, aldosterone synthase inhibitors, and the third and fourth generation of mineralocorticoid receptor antagonists. The results of the experimental and clinical studies are encouraging, which leads us to believe that these new molecules can support the treatment of cardiovascular diseases as well as cardiometabolic disorders.

Source: Experimental Biology and Medicine - October 3, 2016 Category: Research Authors: Gromotowicz-Poplawska, A., Szoka, P., Kolodziejczyk, P., Kramkowski, K., Wojewodzka-Zelezniakowicz, M., Chabielska, E. Tags: Minireview Source Type: research